Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Active Biotech AB's Debt-to-Equity or its related term are showing as below:
FRA:BTP'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.12 Max: 2.71
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of Active Biotech AB was 2.71. The lowest was 0.02. And the median was 0.12.
FRA:BTP's Debt-to-Equity is ranked better than 75.05% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:BTP: 0.04
Active Biotech AB (FRA:BTP) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Active Biotech AB Debt-to-Equity Related Terms
Active Biotech AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Active Biotech AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BTP vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Active Biotech AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Active Biotech AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Active Biotech AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Active Biotech AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Active Biotech AB (FRA:BTP) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Active Biotech AB and its competitors. Over the past decade, Active Biotech AB's Debt-to-Equity has ranged from 0.02 to 2.71. According to the industry distribution chart, Active Biotech AB ranks #241 out of 966 companies in the Biotechnology industry, placing it in the top 24.9%.
Is Active Biotech AB's Debt-to-Equity too high?
Active Biotech AB's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 2.71. Based on the distribution chart, Active Biotech AB ranks #241 out of 966 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Active Biotech AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Active Biotech AB ranks #241 out of 966 companies for Debt-to-Equity. This places Active Biotech AB in the top 25% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Historically, Active Biotech AB's own Debt-to-Equity has ranged from 0.02 to 2.71 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Active Biotech AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Active Biotech AB's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Based on GuruFocus' analysis, Active Biotech AB (FRA:BTP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.45 — trading 242.7% above its estimated fair value. The current Debt-to-Equity is 0.00. Active Biotech AB's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Active Biotech AB (FRA:BTP), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Active Biotech AB (FRA:BTP) Overvalued in 2026?
Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued.
The current stock price of €0.45 is trading 242.7% above its estimated GF Value™ of €0.13.
GuruFocus considers Active Biotech AB to be Significantly Overvalued.
Key valuation signals for FRA:BTP:
Debt-to-Equity: 0.00
GF Value™: €0.13 vs. price of €0.45 (242.7% above fair value)
No single metric tells the full story. See the FRA:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
34GF Score
Get the complete analysis for FRA:BTP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BTP has been successfully added to your 
